Human NFkB (p105 / p50) Antibody Pair - BSA and Azide free (ab253505)
Key features and details
- Unconjugated capture and detector antibodies
- Adaptable to any antibody pair-based assay format
- Antibody concentration ~ 1 mg/ml
- BSA and azide free buffer - ready for conjugation
- Reacts with: Human
Overview
-
Product name
Human NFkB (p105 / p50) Antibody Pair - BSA and Azide free
See all NFkB p105 / p50 kits -
Assay type
ELISA set -
Range
19.531 pg/ml - 1250 pg/ml -
Species reactivity
Reacts with: Human -
Product overview
- Human NFkB Antibody Pair is a matched pair of unconjugated recombinant rabbit monoclonal capture and detection antibodies used to quantify Human NFkB in sandwich ELISAs and many other pair-based applications.
- The pair can be used in variety of assays and platforms including but not limited to:
- - Sandwich ELISA
- - FRET/TR-FRET/HTR
- - Meso Scale Discovery® (MSD®)
- - Luminex® and bead-based assays
- - AlphaLISA®/AlphaScreen®
- - DELFIA® immunoassays
- - Simoa® and Single Molecule Counting (SMC™) immunoassays
- - Multiplex
- Our antibody pairs are supplied in a carrier-free format that is conjugation-ready:
- - Buffer free of BSA, sodium azide, and glycerol for higher conjugation efficiency.
- - Concentration of ~1 mg/ml as measured by the protein A280 method.
- Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with
- We can label antibodies for you: get in touch today to discuss how we can help accelerate your assay development with custom conjugation services.
- Pairs are screened in biological samples, including plasma and serum, to ensure specificity in complex samples.
- Please note:
- The recommended antibody orientation is based on internal optimization in sandwich ELISA. Antibody orientation is assay dependent and needs to be optimized for each assay type.
- The range provided for this antibody pair is based on initial sandwich ELISA validation data using recombinant protein. Performance and range of the antibody pair will depend on the specific characteristics of your assay, including standard protein selection.
- We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibodies in other assays.
- Antibody properties:
- Capture antibody: recombinant rabbit monoclonal (unconjugated) – 100 µg
- Detector antibody: recombinant rabbit monoclonal (unconjugated) - 100 µg
- Concentration: ~1 mg/ml
- Storage buffer: 100% PBS
- Form: Liquid
- Isotype: IgG
- Recombinant monoclonal antibodies offer several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
- For more information see here.
- Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
- Meso Scale Discovery and MSD are registered trademarks of Meso Scale Diagnostics, LLC.
- Luminex is a trademark of Luminex Corporation, registered in the US and other countries.
- AlphaLISA, AlphaScreen, and DELFIA are registered trademarks of PerkinElmer, Inc.
- Simoa is a registered trademark of Quanterix, Inc.
- SMC is a registered trademark of Merck KGaA, Darmstadt, Germany.
-
Tested applications
Suitable for: Sandwich ELISAmore details -
Platform
Reagents
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Carrier free
Yes -
Components 10 x 96 tests Human Nuclear factor NF-kappa-B p105 subunit Capture Antibody (unconjugated) 1 x 100µl Human Nuclear factor NF-kappa-B p105 subunit Detector Antibody (unconjugated) 1 x 100µl -
Research areas
-
Function
NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105. -
Sequence similarities
Contains 7 ANK repeats.
Contains 1 death domain.
Contains 1 RHD (Rel-like) domain. -
Domain
The C-terminus of p105 might be involved in cytoplasmic retention, inhibition of DNA-binding, and transcription activation.
Glycine-rich region (GRR) appears to be a critical element in the generation of p50. -
Post-translational
modificationsWhile translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.
Polyubiquitination seems to allow p105 processing.
S-nitrosylation of Cys-61 affects DNA binding. -
Cellular localization
Nucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor. - Information by UniProt
-
Alternative names
- DKFZp686C01211
- DNA binding factor KBF1
- DNA binding factor KBF1 EBP1
see all -
Database links
- Entrez Gene: 4790 Human
- Omim: 164011 Human
- SwissProt: P19838 Human
- Unigene: 618430 Human
Images
-
To learn more about the advantages of recombinant antibodies see here.